MOH
Molina Healthcare Inc
$228.27
▼ 0.7%Updated Today 12:11 PM ET
MOH at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 28/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 5.0% over the last 12 months
Market Cap
$11.98B
P/E
62.67x
Forward P/E (est.)
89.53x
ROE
4.4%
Revenue Growth
7.7%
EPS Growth
-83.7%
Profit Margin
0.4%
FCF Yield
8.3%
Debt / Equity
0.98x
ROIC
11.0%
Interest Coverage
7.17x
Current Ratio
1.63x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
28/100
Molina Healthcare Inc (MOH) is a large-cap company in the Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $11.98B.
In its latest reported year it generated about $45.43B in revenue and $472.00M in net profit.
Our model rates MOH Weak (28/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what MOH's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. MOH trades near $228.27, above its 50-day average ($194.64) and 200-day average ($170.04). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. MOH's is $8.43 (~3.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month MOH found buyers near $190.00 (support) and sellers near $236.26 (resistance); its 52-week range is $121.06–$242.56. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
13.1%
Revenue moved from $17.78B in 2016 to $45.43B in 2025, a 11.0% compound annual growth rate. The most recent year grew a steady 7.7% year over year. Slower, mature growth is common for established businesses.
Gross Margin
12.9%
Operating Margin
1.7%
Net Margin
1.0%
ROE
4.4%
Molina Healthcare Inc keeps about 0.4% of each sales dollar as net profit, with a 12.9% gross margin and 1.7% operating margin. Return on equity is 4.4% and return on invested capital about 11.0%. Thin margins leave less cushion if costs rise.
Total Debt
$1.65B
Net Debt
-$3.66B
Net cash position
Net Debt / EBITDA
-4.69x
Debt / Equity
0.98x
Leverage: debt-to-equity is 1.0x, and operating profit covers interest about 7.2x, with a current ratio of 1.6x. That is a moderate, manageable debt load for most businesses. It carries roughly $1.65B of total debt against $5.31B of cash.
Operating CF
-$535.00M
Free Cash Flow
-$636.00M
FCF Margin
-1.4%
In the latest year Molina Healthcare Inc produced about -$535.00M of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about 8.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
62.67x
P/S
0.26x
P/B
2.19x
EV / EBITDA
8.52x
MOH trades at 62.7x trailing earnings (about 89.5x on estimated forward earnings), 0.3x sales, and 2.2x book value. That is a rich multiple that prices in a lot of future growth.
Where MOH sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 53 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How MOH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (198 S&P 500 companies), MOH ranks #50 of 198 by our overall rating. It trades at a premium versus the sector on earnings (62.7x P/E vs. 25.5x median) with a lower return on equity (4.4% vs. 14.5%) and faster revenue growth (7.7% vs. 7.6%).
P/E vs sector
62.7x
median 25.5x
ROE vs sector
4.4%
median 14.5%
Growth vs sector
7.7%
median 7.6%
Sector rank
#50
of 198 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 198 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $228.27 today · expected CAGR 45% – 60%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $49.06B | $52.98B | $57.22B | $61.80B | $66.75B |
| Net income | $1.47B | $1.59B | $1.72B | $1.85B | $2.00B |
| EPS | $28.25 | $30.51 | $32.95 | $35.59 | $38.43 |
| Share price (low) | $1,073.48 | $1,159.36 | $1,252.11 | $1,352.28 | $1,460.46 |
| Share price (high) | $1,779.72 | $1,922.10 | $2,075.87 | $2,241.94 | $2,421.29 |
| CAGR (low–high) | 370% / 680% | 125% / 190% | 76% / 109% | 56% / 77% | 45% / 60% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for MOH:
- Healthy free-cash-flow yield (~8.3%) funds buybacks and dividends.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against MOH:
- Thin net margins (0.4%) leave little room for error.
- A rich 62.7x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (28/100).
Valuation risk — at 62.7x earnings, disappointing results could compress the multiple.
Margin risk — thin profitability (0.4%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Molina Healthcare Inc is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 62.7x earnings, which our model scores Weak (28/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
MOH — frequently asked questions
Is MOH a good stock to buy?
We don't give buy or sell advice. Our model rates Molina Healthcare Inc Weak (28/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is MOH's rating on The Stocks School?
Molina Healthcare Inc currently scores 28/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does MOH's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Molina Healthcare Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for MOH calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this MOH analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell MOH. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.